STOCK TITAN
  1. Home
  2. News
  3. B

Barnes Group Inc. - B STOCK NEWS

Welcome to our dedicated news page for Barnes Group (Ticker: B), a resource for investors and traders seeking the latest updates and insights on Barnes Group.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Barnes Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Barnes Group's position in the market.

News
Barnes Reports First Quarter 2024 Financial Results
Rhea-AI Summary
Barnes Group Inc. reports strong first-quarter 2024 financial results with sales of $431 million, up 28%, driven by Aerospace growth. Operating margin increased to 9.2%, adjusted EBITDA margin up to 18.7%. Adjusted EPS down 19% to $0.38. Aerospace segment sales surged 89%, while Industrial segment reported a 4% decline. Company divested Associated Spring & Hanggi businesses to focus on Aerospace. Balance sheet shows $82 million in cash and $344 million available credit. Updated 2024 guidance includes organic sales growth of 5% to 8%, adjusted EPS of $1.62 to $1.82, and capital expenditures of $60 million to $70 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
Rhea-AI Summary
BioArctic AB's partner Eisai reported Leqembi's global revenue of JPY 2.83 billion in the first quarter of 2024, resulting in a royalty of approximately SEK 18 million for BioArctic. Eisai and Biogen co-commercialize the product, with BioArctic holding commercialization rights in the Nordic region pending European approval. BioArctic and Eisai are preparing for joint commercialization in the region. BioArctic's first-quarter 2024 report will be released on May 17, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
Rhea-AI Summary
BioArctic and Eisai have signed a research evaluation agreement for BAN2802, a potential Alzheimer's treatment combining BrainTransporter™ technology with an undisclosed drug candidate. The collaboration aims to develop the next generation disease-modifying treatment for Alzheimer's disease. Eisai will evaluate the data to potentially license BAN2802, building on their successful partnership that led to the approval of Leqembi® for early Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
Rhea-AI Summary
BioArctic AB's Nomination Committee proposes the election of board members and Chairperson for the upcoming Annual General Meeting. The proposed board consists of seven members, including a new member, Anna-Lena Engwall, with extensive experience in the life science and pharmaceutical industry. The Nomination Committee aims to enhance the board's expertise and network through these appointments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
management
-
News
Barnes Aerospace Announces Expanded Aero Engine MRO Facility – East Granby, Connecticut
Rhea-AI Summary
Barnes Aerospace completes expansion of its MRO facility in East Granby, Connecticut, adding 32,000 square feet of manufacturing space. The facility now totals over 84,000 square feet and specializes in complex repairs for commercial and military engine platforms. Upgrades include a new chemical cleaning line to enhance capabilities and meet growing demand for engine programs and product lines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.16%
Tags
none
-
News
One Equity Partners Completes Acquisition of Associated Spring
Rhea-AI Summary
One Equity Partners (OEP) completes the acquisition of Associated Spring from Barnes Group Inc., a leading manufacturer of custom parts for industrial, medical, and automotive applications. The Company has a global footprint with over 800 employees and plans for organic growth and add-on acquisitions. The aerospace and medical markets show promising growth trends, with OEP aiming to establish Associated Spring as a market leader.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
acquisition
News
Barnes Announces Completion of Previously Announced Sale of Associated Spring™ and Hänggi™ Businesses
Rhea-AI Summary
Barnes Group Inc. (NYSE: B) completes the sale of Associated Spring and Hänggi businesses to One Equity Partners for $175 million, aiming to enhance shareholder value. The net cash proceeds of $140 million will be utilized to reduce debt, aligning with the company's strategy to optimize its portfolio and drive profitable growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
none
-
News
Hexagon rebrands Qognify, reaffirming commitment to physical security
Rhea-AI Summary
Qognify adopts Hexagon's corporate identity, enhancing innovation and value for customers. The integration offers a wide range of physical security solutions, expanding situational awareness and risk mitigation for over 4,000 organizations globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
none
-
News
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed
Rhea-AI Summary
Eisai submits sBLA for monthly IV maintenance dosing of Leqembi for Alzheimer's disease treatment. The application is based on Phase 2b and Clarity AD studies data. Fast Track designation sought for SC formulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
News
Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons
Rhea-AI Summary
BioArctic AB's partner Eisai faces procedural delays at EMA for lecanemab review, impacting SAG-N meeting. The decision does not affect the Marketing Authorisation Application for lecanemab. BioArctic and Eisai collaborate on lecanemab development, with BioArctic having commercialization rights in the Nordic region.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
Stock B logo
Barnes Group Inc.

NYSE:B

B Rankings

#1940 Ranked by Market Cap
#4450 Ranked by Stock Gains
#1496 Ranked by Dividends

B Stock Data

1.72B
45.58M
9.12%
92.61%
2.06%
Aircraft Engine and Engine Parts Manufacturing
Manufacturing
Link
US
Bristol

About B

barnes group inc. is an international industrial and aerospace manufacturer and service provider, serving a wide range of end markets and customers. the highly engineered products, differentiated industrial technologies, and innovative solutions delivered by barnes group are used in far-reaching applications that provide transportation, manufacturing, healthcare products, and technology to the world. with approximately 4,700 dedicated employees, at more than 60 locations worldwide, on four continents across the globe, barnes group continues to build on our long-standing tradition of excellence in precision manufacturing and logistics solutions, while at the same time, investing in leading-edge technologies and applying our expertise in newer break-through markets. barnes group operates under two global business segments - industrial and aerospace. at barnes group, there are no limits to your career path - only opportunities for success! explore your future and career potential at